China Securities Journal, China Securities Network (Reporter Fu Suying) – On December 7, Huadong Medicine's wholly-owned subsidiary Huadong Medicine (Hangzhou) Co., Ltd. announced that it has entered into an exclusive commercialization partnership for mainland China with Guizhou Sinorda Biotech Co., Ltd. and its wholly-owned subsidiaries Shanghai Sinorda Pharmaceutical Technology Co., Ltd. and Jiangsu Taris Sinorda Biopharmaceutical Co., Ltd. (collectively referred to as "Sinorda Pharma"). The partnership covers Sinorda's product Linaprazan Glutarate Capsules and other dosage forms.

Linaprazan is a next-generation potassium-competitive acid blocker (P-CAB) drug co-developed by Sinorda Pharma and Cinclus Pharma for the treatment of digestive system diseases. Leveraging Huadong Medicine's strong commercialization platform, Linaprazan is expected to achieve rapid market uptake and will further enhance Huadong Medicine's product portfolio in the digestive disease field.

On December 7, the National Healthcare Security Administration disclosed that Linaprazan, indicated for gastroesophageal reflux disease, and the PARP inhibitor Senaparib (Paisuning®) have been included in the 2025 National Reimbursement Drug List. Meanwhile, Zevorcabtagene Autoleucel Injection (brand name: Saikaize®) has been included in the 2025 Commercial Health Insurance Innovative Drug Directory. Huadong Medicine has established an independent, professional, and comprehensive commercialization team to fully promote Saikaize®, utilizing China's multi-tier insurance system to improve patient accessibility. Currently, medical institutions certified and filed for Saikaize® cover more than 20 provinces and cities nationwide.

In recent years, Huadong Medicine has focused its innovative R&D on three core therapeutic areas: oncology, endocrine, and autoimmune diseases. Through internal R&D, external collaboration, and in-licensing, the company continues to enrich a differentiated innovative product pipeline spanning the entire R&D lifecycle, providing new momentum for medium- to long-term growth. The company's independent R&D capabilities are continuously improving, with its innovative drug R&D center advancing over 90 pipeline projects.

On the commercialization execution front, Huadong Medicine possesses strong market promotion capabilities, consistently driving rapid post-launch uptake of multiple core products and unleashing steady commercial growth momentum. In the first three quarters of 2025, the company's total revenue from innovative pharmaceutical product sales and agency services reached RMB 1.675 billion, a significant year-on-year increase of 62%.

The company's exclusively commercialized CAR-T product, Zevorcabtagene Autoleucel Injection (brand name: Saikaize®), has maintained a strong market position since its launch. As of the third quarter of 2025, the company has placed 170 valid orders to its partner CARsgen Therapeutics, already surpassing the total number of orders placed in the entire previous year.

Reference: https://finance.eastmoney.com/a/202512083585106694.html